See also:
order cialis |
cialis |
Article Courtesy of The Earth Times Online NewspaperPreliminary Analysis of rEEG(R) Guided Medication
Study Demonstrates an Improvement in
Depression and Eating Disorder SymptomsCOSTA MESA, Calif., May 22
COSTA MESA, Calif., May 22 /PR Newswire-FirstCall/ --
CNS Response, Inc. (OTC Bulletin Board: CNSO) reported today
the results of a study presented at the American
Psychiatric Association (APA) 161st Annual Meeting
by Dr. James Greenblatt, M.D., Chief Medical Officer,
Walden Behavioral Care Inpatient Psychiatry and
Eating Disorder Programs. The poster presentation,
titled "
Referenced-EEG Guided Medication Predictions
in Treatment Refractory Eating Disorder Patients,"
provided a preliminary analysis of a patient-controlled
case series studying the use of Referenced-EEG (rEEG(R))
to facilitate the medication selection for patients
with eating disorders and comorbid depression.
The study of eight female patients, conducted over up
to a four-year period, demonstrated that rEEG
successfully guided physician selection of each
patient's medications in the series, leading to
a dramatic relief of depression and eating
disorder symptoms. Successful rEEG-guided
predictions involved medications in the
anticonvulsant, antidepressant and stimulant
classes, often in combination.
Dr. Greenblatt commented, "Despite the small
sample size of this study, the results support
the promise of rEEG as an effective tool for
determining medication programs for treatment
refractory patients with eating disorders
and depression. The decrease in depressive
symptoms, as well as significant improvement
in eating disorders symptoms and weight, for
the eight patients in the trial was striking,
considering that, prior to the study, each had
required either partial hospitalization or
inpatient care, as determined by managed behavioral
health care reviewers. However, following rEEG
medication recommendations, hospitalization days
for the patients decreased dramatically. Anorexia
nervosa is a potentially fatal illness with significant
mortality if early interventions are not successful.
Improved pharmacology, as these cases demonstrate,
could decrease the high morbidity and mortality
in patients with disordered eating."
Primary outcome measures of the study included the
21-item Hamilton Rating for Depression Scale (HDRS)
and the Clinical Global Improvement Scale (CGI)
and the Clinical Global Severity Scale (SGS).
Some of the criteria used to assess improvement
in the CGI included: body dissatisfaction,
drive for thinness, compulsive exercising, binging
and purging.
Improvements in both HDRS and CGI scores were evident
at 8-weeks,6-months, and 2 years (for 4 patients).
The medications selected from rEEG correlations
involved combinations from many different classes
of medications. Stimulant medications in four
Eating Disorder patients did not result in appetite
suppression or weight loss. These results are consistent
with recent findings that ADHD can predict eating disorder
pathology in adolescent girls.
Greenblatt continued, "Specific patient progress during
the study demonstrated the ability of rEEG to have a
real impact on the lives of those with severe mental
conditions. One anorexia nervosa patient had previously
received five different medication regimes, none of
which provided any improvement. The patient had been
hospitalized on five separate occasions during the two
years prior to rEEG testing. Based on the rEEG report,
we medicated the patient with a combination of
Oxcarbazepine and Duloxetine.
This treatment combination is outside of the traditional
medications we would have considered. In fact, there
are no medications that have shown consistent success
in treatment of anorexia nervosa. For the 24 months
following, the patient did not require further
hospitalization, and at the end of the 24 months was
rated as 'Normal.'
"The two Bulimia Nervosa patients in the study had seven
hospitalizations between them, but neither required
further hospital care after being treated by the rEEG
guided medications personalized to their own brain
function. We would never have known or even considered
these medications without the guidance of this rEEG
analysis and associated reports."
Len Brandt, Chairman and CEO of CNS Response, noted,
"I congratulate Dr.Greenblatt on his accomplishments
in this study in which he documented the benefits of
personalized medication selection based on analysis
of brain physiology. It is not only the dramatic
improvement demonstrated in this study that makes it
a compelling analysis, but also that he had carefully
documented treatment history on these patients for two
years prior to rEEG analysis. Generally, researchers
lack accurate treatment histories for patients recruited
to a study, and comparisons of previous treatments
to a new treatment approach cannot be made. The best
alternative is to compare two patient groups that
are randomly assigned different treatment regimes,
ignoring comparisons to historical response to treatment.
Results are typically measured over a fairly short
period of eight to twelve weeks, but rating
improvements are challenging as unique patient history
and symptom manifestation data is unavailable.
"In this study, however, Dr Greenblatt carefully
recorded treatment histories for 24 months prior to
the rEEG analysis. He then measured patients' responses
to the rEEG-guided medications and associated
therapies for 6 to 24 months post initial dosing,
demonstrating not just treatment response, but also
that the response was durable. The long term record
of pre-rEEG treatment history compared to post-rEEG
treatment makes this a notable study.
"Though a small group of patients were involved in this
study, considering the quality of the study - the
established treatment history prior to rEEG analysis,
the durability of treatment response demonstrated
over the 6 to 24 months following the rEEG-guided
medication selection, the severity of illness present
in these patients with both eating disorders
and depression, and the consistent degree of benefit
realized by these patients - we are encouraged that
such treatment-resistant patients,
their families and their physicians can hope for a
truly personalized medicine approach. We are proud to
recognize Dr. Greenblatt's disciplined
commitment to this effort and look forward to his report
on an additional group of patients that have not yet
reached the six months response mark."
Daniel Hoffman, MD, Chief Medical Officer for CNS
Response, concluded, "This is the second scientific
poster to report on the benefit of rEEG-guided
personalized medicine for the eating disordered
population. The previous poster reported on results
in a residential care setting where 61 of 81 (75%)
had been successfully treated with rEEG guided medication
selection. I expect psychiatrists treating such
challenging cases will appreciate Dr. Greenblatt's
efforts concerning an even more severely disabled patient
group. This is a population for which there are essentially
no known medication treatments, other than fluoxetine for
bulimia, yet represents one of the most lethal groups we treat."
The full poster presentation and analysis of results
are available via:
http://www.cnsresponse.com/uploads/assets/0000/0066/rEEGEDPosterCNSR2008.pdfRead the article in full
here.SOURCE CNS Response, Inc.
More information on rEEG
here.
sources: http://www.earthtimes.org/articles/show/cns-response-inc-provides-review,405290.shtml http://www.neuropsychiatryreviews.com/may06/rEEG.html
Picture source: http://psyphz.psych.wisc.edu/~greischar/BIW12-11-02/SagElect.bmpMy apologies to anyone who may have received this
post by subscription and was sent severalcopies. It was due to a problem with
formatting (which hopefully is now rectified).
